CN1733194A - Extract of combined Chinese traditional medicinal crops for curing diseases of respiratory system and extracting method - Google Patents
Extract of combined Chinese traditional medicinal crops for curing diseases of respiratory system and extracting method Download PDFInfo
- Publication number
- CN1733194A CN1733194A CN 200410041734 CN200410041734A CN1733194A CN 1733194 A CN1733194 A CN 1733194A CN 200410041734 CN200410041734 CN 200410041734 CN 200410041734 A CN200410041734 A CN 200410041734A CN 1733194 A CN1733194 A CN 1733194A
- Authority
- CN
- China
- Prior art keywords
- extract
- cough
- chinese medicine
- traditional chinese
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 37
- 201000010099 disease Diseases 0.000 title abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 5
- 210000002345 respiratory system Anatomy 0.000 title abstract description 3
- 239000008187 granular material Substances 0.000 claims abstract description 109
- 239000007788 liquid Substances 0.000 claims abstract description 44
- 241001633583 Adenophora Species 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000007901 soft capsule Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 57
- 239000000463 material Substances 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000341 volatile oil Substances 0.000 claims description 38
- 208000023504 respiratory system disease Diseases 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 15
- 229950005162 benexate Drugs 0.000 claims description 10
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 239000001116 FEMA 4028 Substances 0.000 claims description 5
- 241000202807 Glycyrrhiza Species 0.000 claims description 5
- 241000207929 Scutellaria Species 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 5
- 229960004853 betadex Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 240000000249 Morus alba Species 0.000 abstract description 111
- 235000008708 Morus alba Nutrition 0.000 abstract description 111
- 244000018633 Prunus armeniaca Species 0.000 abstract description 4
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract description 4
- 244000061508 Eriobotrya japonica Species 0.000 abstract 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000244269 Peucedanum Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 134
- 241000699666 Mus <mouse, genus> Species 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 206010006451 bronchitis Diseases 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000012449 Kunming mouse Methods 0.000 description 9
- 206010035664 Pneumonia Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 206010036790 Productive cough Diseases 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 241000712431 Influenza A virus Species 0.000 description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 208000007451 chronic bronchitis Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000009254 shuang-huang-lian Substances 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000194103 Bacillus pumilus Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 241001092070 Eriobotrya Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229940100050 virazole Drugs 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000192087 Staphylococcus hominis Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000013010 irrigating solution Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an extract of combined Chinese traditional medicinal herbs for curing diseases of respiratory system and extracting method, wherein the extract is prepared from mulberry leaf, dried orange peel, mulberry leaf, dried orange peel, peucedanum root, loquat leaves, adenophora root, pinellia tuber, licorice root, baikal skullcap root, apricot seeds, thunberg fritillary bulb, root of ballon flower. The extract can be made into various dosage types including granules, capsules, tablets, soft capsules and oral liquids.
Description
Technical field
The present invention relates to the extract and the extracting method of combined traditional Chinese medicine material, particularly treat the extract and the extracting method of the combined traditional Chinese medicine material of respiratory system disease.
Background technology
Respiratory system disease is a kind of commonly encountered diseases, frequently-occurring disease, and along with the modern industry development, air pollution is serious day by day.Extraneous harmful substance directly sucks pulmonary as various harmful gass, dust, sensitization microorganism and sensitinogen, and respiratory system sickness rate and case fatality rate are all being increased.China's rural area sampling survey in 1998 shows that the respiratory system disease mortality rate occupy the first, accounts for 25% of general mortality rate.What area, Shanghai resident's hospital admission accounted for the first place also is respiratory tract disease.According to incompletely statistics, this disease adult's sickness rate is 5%, and old man and child's sickness rate is higher.Respiratory system disease such as acute bronchitis, acute episode of chronic bronchitis mainly is because due to the heresy criminal lung of wind, cold, summer-heat, wet, dry, fiery six gas.Wind, cold, summer-heat, wet, dry, fiery six gas all can cause and cough, and respiratory system diseases such as acute bronchitis, acute episode of chronic bronchitis are not prolonged for a long time more can transfer the endogenous cough to, and the endogenous cough feels exopathogen again, easily bring out again and increase the weight of.But because the difference of climate change in 4 o'clock, the pathogenic exopathogen that human body is experienced is also had any different, thus clinically wind and cold is arranged, wind heat and different coughs such as scorching.No matter because wind and cold, wind heat or scorching how based on wind, are held exopathogen invasions such as cold, hot, dry under the arm, hinder in lung and be and be cough.In recent years to respiratory system disease common cough, expectorant, the etiology and pathology breathed heavily is learned and mutual relation has had further understanding, also tries out multiple therapy, but still based on Drug therapy.The new drug that respiratory system disease is developed recent years is quite a few, but curative effect is still not ideal enough.In the prior art, though some clinical experience prescriptions are arranged, the composition in the drug effect side is because of unpredictable factors such as the place of production, climates, uncontrollable stabilized quality and curative effect.But medication extremely is inconvenience.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, by to eliminating pathogen for dispersing lung-QI, the clinical experience prescription of respectful lung cough-relieving carry out the pharmacological research screening, improve the curative effect of respiratory system diseases such as treatment acute bronchitis, acute episode of chronic bronchitis.A kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease proposed.
The objective of the invention is to be reached by following technical scheme, the present invention is a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, be characterized in that the formulation by weight of combined traditional Chinese medicine material extract raw material is:
Folium Mori 400～600 Radix Peucedanis 400～600 Radix Scutellariaes 400～600
Semen Armeniacae Amarum 400～600 Radix Platycodoniss 160～240 Bulbus Fritillariae Thunbergiis 400～600
Folium Eriobotryae 400～600 Radix Adenophoraes 400～600 Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s 400～600
Pericarpium Citri Reticulatae 240～360 Radix Glycyrrhizaes 120～180
(a) Folium Mori, Pericarpium Citri Reticulatae added 4～8 times of water gagings immersions after 2～4 hours, and steam distillation extracts volatile oil, collects the distillate of 4～10 times of amounts, and distillate gets Folium Mori and Pericarpium Citri Reticulatae volatile oil after redistillation-cold preservation;
(b) get after medicinal residues after the distillation of above-mentioned Folium Mori, Pericarpium Citri Reticulatae and Radix Peucedani, Folium Eriobotryae, Radix Adenophorae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae soak 0.5～2.0 hour, decoct 2～4 times, each 2～3 hours, each 4～8 times of amounts of water, collecting decoction, filter, filtrate is concentrated into 50 ℃ of following relative densities 1.05～1.1, gets water extract; Get Radix Scutellariae, Semen Armeniacae Amarum, Bulbus Fritillariae Thunbergii, Radix Platycodonis, add 50～80% soak with ethanol earlier after 0.5～2.0 hour, heating and refluxing extraction 2～4 times, each 1.0～2.0 hours, each ethanol consumption was 4～7 times of amounts, merge extractive liquid,, filter, decompression filtrate recycling ethanol, and be concentrated into 50 ℃ of following relative densities 1.05～1.1, get alcohol extract; Merge above water extract, alcohol extract, mixing gets combined traditional Chinese medicine material liquid extract;
Said method is the extracting method of extract of the combined traditional Chinese medicine material of described treatment respiratory system disease; Folium Mori and Pericarpium Citri Reticulatae volatile oil and combined traditional Chinese medicine material liquid extract are the extract of the combined traditional Chinese medicine material of described treatment respiratory system disease.
Purpose of the present invention is further reached by following technical scheme, extract and extracting method according to the combined traditional Chinese medicine material of aforesaid treatment respiratory system disease, be characterized in by beta-schardinger dextrin-: Folium Mori and Pericarpium Citri Reticulatae volatile oil are 6～9: 1 weight ratio, under 20～40 ℃ enclose temperature, Folium Mori and Pericarpium Citri Reticulatae volatile oil beta-cyclodextrin inclusion compound that (a) step is obtained, the enclose time is 2.5～3.5 hours, gets the Benexate Hydrochloride of Folium Mori and Pericarpium Citri Reticulatae volatile oil; The combined traditional Chinese medicine material liquid extract that (b) step is obtained concentrates again, and drying is pulverized the Benexate Hydrochloride that adds Folium Mori and Pericarpium Citri Reticulatae volatile oil, and mixing is granulated, and makes the described granule of pharmaceutics, capsule and tablet.
Purpose of the present invention is further reached by following technical scheme, extract and extracting method according to the combined traditional Chinese medicine material of aforesaid treatment respiratory system disease, be characterized in that the combined traditional Chinese medicine material liquid extract that (b) step is obtained adds dispersant, add Folium Mori and the Pericarpium Citri Reticulatae volatile oil that (a) step obtains again, mixing is made soft capsule.
Purpose of the present invention is further reached by following technical scheme, extract and extracting method according to the combined traditional Chinese medicine material of aforesaid treatment respiratory system disease, be characterized in that the combined traditional Chinese medicine material liquid extract that (b) step is obtained adds Folium Mori and the Pericarpium Citri Reticulatae volatile oil that (a) step obtains, and makes oral liquid by the described conventional method of pharmaceutics.
The present invention compared with prior art, the present invention establishes method of treatment according to above-mentioned theory of Chinese medical science, wherein screening is eliminating pathogen for dispersing lung-QI, the pharmacological research that carries out of the clinical experience prescription of respectful lung cough-relieving screens, respiratory system diseases such as being used for acute bronchitis, acute episode of chronic bronchitis is clinically made novel form through the medical material of proved recipe through modernized extraction process, improved clinical efficacy.And, worked out comparatively objectively quality standard according to its composition status of medicine in prescription and the physicochemical property of contained active component thereof, the quality and the curative effect of stable and controllable arranged.Select dosage form of the present invention for use.It has not only kept the characteristic of decoction, and improves curative effect, reduces the medication volume, facilitates patients; Overcome the preceding interim decoction of decoction clothes, the mould shortcoming that loses apt to deteriorate, helped producing in enormous quantities and storing.Experiment is proof also, and the preparation that the extract of combined traditional Chinese medicine material of the present invention makes is having definite curative effect aspect the respiratory system diseases such as acute bronchitis, acute episode of chronic bronchitis.
The specific embodiment
Be embodiments of the invention below, further describe summary of the invention of the present invention.
Embodiment one, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, and weight (gram) prescription of combined traditional Chinese medicine material extract raw material is:
Folium Mori 500 Radix Peucedanis 500 Radix Scutellariaes 500 Semen Armeniacae Amarums 500
Radix Platycodonis 200 Bulbus Fritillariae Thunbergiis 500 Folium Eriobotryaes 500 Radix Adenophoraes 500
Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 500 Pericarpium Citri Reticulataes 300 Radix Glycyrrhizaes 150
(a) Folium Mori, Pericarpium Citri Reticulatae added 6 times of water gagings immersions after 3 hours, and steam distillation extracts volatile oil, collects the distillate of 6 times of amounts, and distillate gets Folium Mori and Pericarpium Citri Reticulatae volatile oil after redistillation-cold preservation;
(b) get after medicinal residues after the distillation of above-mentioned Folium Mori, Pericarpium Citri Reticulatae and Radix Peucedani, Folium Eriobotryae, Radix Adenophorae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae soak 1 hour, decoct each 2.5 hours 3 times, each 7 times of amounts of water, collecting decoction filters, filtrate is concentrated into 50 ℃ of following relative densities 1.08, gets water extract; Get Radix Scutellariae, Semen Armeniacae Amarum, Bulbus Fritillariae Thunbergii, Radix Platycodonis, add 60% soak with ethanol earlier after 1 hour, heating and refluxing extraction 3 times, each 1.8 hours, each ethanol consumption is 6 times of amounts, and merge extractive liquid, filters, decompression filtrate recycling ethanol, and be concentrated into 50 ℃ of following relative densities 1.08, get alcohol extract; Merge above water extract, alcohol extract, mixing gets combined traditional Chinese medicine material liquid extract.
Embodiment two, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, by beta-schardinger dextrin-: Folium Mori and Pericarpium Citri Reticulatae volatile oil are 8: 1 weight ratio, under 30 ℃ enclose temperature, Folium Mori and Pericarpium Citri Reticulatae volatile oil beta-cyclodextrin inclusion compound that (a) step among the embodiment one is obtained, the enclose time is 3 hours, gets the Benexate Hydrochloride of Folium Mori and Pericarpium Citri Reticulatae volatile oil; The combined traditional Chinese medicine material liquid extract that (b) step among the embodiment one is obtained concentrates again, and drying is pulverized the Benexate Hydrochloride that adds Folium Mori and Pericarpium Citri Reticulatae volatile oil, and mixing is granulated, and makes the described granule of pharmaceutics, capsule and tablet.
Embodiment three, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, by beta-schardinger dextrin-: Folium Mori and Pericarpium Citri Reticulatae volatile oil are 6: 1 weight ratio, under 20 ℃ enclose temperature, Folium Mori and Pericarpium Citri Reticulatae volatile oil beta-cyclodextrin inclusion compound that (a) step among the embodiment one is obtained, the enclose time is 2.5 hours, gets the Benexate Hydrochloride of Folium Mori and Pericarpium Citri Reticulatae volatile oil; The combined traditional Chinese medicine material liquid extract that (b) step among the embodiment one is obtained concentrates again, and drying is pulverized the Benexate Hydrochloride that adds Folium Mori and Pericarpium Citri Reticulatae volatile oil, and mixing is granulated, and makes the described granule of pharmaceutics, capsule and tablet.
Embodiment four, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, by beta-schardinger dextrin-: Folium Mori and Pericarpium Citri Reticulatae volatile oil are 9: 1 weight ratio, under 40 ℃ enclose temperature, Folium Mori and Pericarpium Citri Reticulatae volatile oil beta-cyclodextrin inclusion compound that (a) step among the embodiment one is obtained, the enclose time is 3.5 hours, gets the Benexate Hydrochloride of Folium Mori and Pericarpium Citri Reticulatae volatile oil; The combined traditional Chinese medicine material liquid extract that (b) step among the embodiment one is obtained concentrates again, and drying is pulverized the Benexate Hydrochloride that adds Folium Mori and Pericarpium Citri Reticulatae volatile oil, and mixing is granulated, and makes the described granule of pharmaceutics, capsule and tablet.
Embodiment five, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, and weight (gram) prescription of combined traditional Chinese medicine material extract raw material is:
Folium Mori 400 Radix Peucedanis 400 Radix Scutellariaes 400 Semen Armeniacae Amarums 600
Radix Platycodonis 160 Bulbus Fritillariae Thunbergiis 600 Folium Eriobotryaes 600 Radix Adenophoraes 400
Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 600 Pericarpium Citri Reticulataes 360 Radix Glycyrrhizaes 120
(a) Folium Mori, Pericarpium Citri Reticulatae added 4 times of water gagings immersions after 4 hours, and steam distillation extracts volatile oil, collects the distillate of 4 times of amounts, and distillate gets Folium Mori and Pericarpium Citri Reticulatae volatile oil after redistillation-cold preservation;
(b) get after medicinal residues after the distillation of above-mentioned Folium Mori, Pericarpium Citri Reticulatae and Radix Peucedani, Folium Eriobotryae, Radix Adenophorae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae soak 0.5 hour, decoct each 2 hours 4 times, each 4 times of amounts of water, collecting decoction filters, filtrate is concentrated into 50 ℃ of following relative densities 1.1, gets water extract; Get Radix Scutellariae, Semen Armeniacae Amarum, Bulbus Fritillariae Thunbergii, Radix Platycodonis, the soak with ethanol that adds 50% weight concentration earlier is after 2 hours, heating and refluxing extraction 2 times, each 2 hours, each ethanol consumption is 7 times of amounts, and merge extractive liquid, filters, decompression filtrate recycling ethanol, and be concentrated into 50 ℃ of following relative densities 1.1, get alcohol extract; Merge above water extract, alcohol extract, mixing gets combined traditional Chinese medicine material liquid extract.
Embodiment six, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, the combined traditional Chinese medicine material liquid extract that (b) step among the embodiment five is obtained adds dispersant, add Folium Mori and Pericarpium Citri Reticulatae volatile oil that (a) step among the embodiment five is obtained again, mixing is made soft capsule.
Embodiment seven, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, and weight (gram) prescription of combined traditional Chinese medicine material extract raw material is:
Folium Mori 600 Radix Peucedanis 600 Radix Scutellariaes 600 Semen Armeniacae Amarums 400
Radix Platycodonis 240 Bulbus Fritillariae Thunbergiis 400 Folium Eriobotryaes 400 Radix Adenophoraes 600
Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 400 Pericarpium Citri Reticulataes 240 Radix Glycyrrhizaes 180
(a) Folium Mori, Pericarpium Citri Reticulatae added 8 times of water gagings immersions after 2 hours, and steam distillation extracts volatile oil, collects the distillate of 10 times of amounts, and distillate gets Folium Mori and Pericarpium Citri Reticulatae volatile oil after redistillation-cold preservation;
(b) get after medicinal residues after the distillation of above-mentioned Folium Mori, Pericarpium Citri Reticulatae and Radix Peucedani, Folium Eriobotryae, Radix Adenophorae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae soak 2 hours, decoct each 3 hours 2 times, each 8 times of amounts of water, collecting decoction filters, filtrate is concentrated into 50 ℃ of following relative densities 1.05, gets water extract; Get Radix Scutellariae, Semen Armeniacae Amarum, Bulbus Fritillariae Thunbergii, Radix Platycodonis, the soak with ethanol that adds 80% weight concentration earlier is after 0.5 hour, heating and refluxing extraction 4 times, each 1 hour, each ethanol consumption was 4 times of amounts, merge extractive liquid,, filter, decompression filtrate recycling ethanol, and be concentrated into 50 ℃ of following relative densities 1.05, get alcohol extract; Merge above water extract, alcohol extract, mixing gets combined traditional Chinese medicine material liquid extract.
Embodiment eight, present embodiment are a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease, the combined traditional Chinese medicine material liquid extract that (b) step among the embodiment seven is obtained adds Folium Mori and the Pericarpium Citri Reticulatae volatile oil that (a) step obtains among the embodiment seven, makes oral liquid by the described conventional method of pharmaceutics.
Effect experiment:
Definition medicament name of the present invention is called in following effect experiment: cough-relieving Mulberry Fructus Pruni granule
One, general introduction
Through Pharmacodynamic test of active extract, that cough-relieving Mulberry Fructus Pruni granule has is antibiotic, antiviral, cough-relieving, eliminate the phlegm, pharmacological action such as antiinflammatory.
1) the in-vitro antibacterial experiment shows, cough-relieving Mulberry Fructus Pruni granule has certain bacteriostasis to bacillus subtilis, staphylococcus aureus, acinetobacter calcoaceticus, table staphylococcus, the false monospore bacillus of Bulbus Allii Cepae, staphylococcus hominis, streptococcus, Bacillus proteus.
2) antibacterial experiment shows in the body, and cough-relieving Mulberry Fructus Pruni granule has significant protective effect to infecting staphylococcus aureus in the mice body.
3) antiviral experiment in inside and outside shows, though the outer demonstration of cough-relieving Mulberry Fructus Pruni granule directly suppresses the effect of influenza A virus, in the body mice influenza virus property pneumonia is all had significant protective effect, points out it to have certain antivirus action.
4) cough-relieving Mulberry Fructus Pruni granule can obviously reduce the cough caused number of times of Cavia porcellus electricity irritation; Prolong the ammonia induced mice and draw and cough incubation period, reduce its cough number of times, have certain antitussive action.
5) cough-relieving Mulberry Fructus Pruni granule can obviously increase airway of mice phenol red output, shows that cough-relieving Mulberry Fructus Pruni granule has the increase airway secretions, promotes the effect that sputum is discharged.Cough-relieving Mulberry Fructus Pruni granule can obviously increase the expectoration amount of rat, shows that cough-relieving Mulberry Fructus Pruni granule has significant resolve phlegm effect.
6) cough-relieving Mulberry Fructus Pruni granule can obviously alleviate dimethylbenzene induced mice ear swelling; Mouse peritoneal capillary permeability due to the inhibition HAc increases, and shows to have certain antiinflammatory action.
Two, experiment purpose
Cure mainly relevant effect by main pharmacodynamics experimental verification cough-relieving Mulberry Fructus Pruni granule with clinical function.
Three, experimental result
3.1 external bacteriostatic experiment
The method 3.1.1 flat board burrows
Get each bacterial strain nutrient broth culture of cultivating in 16 hours, do 10 with nutrient broth
-3Dilution is used for experiment, in the sterilization plate of diameter 9cm, add bacterium liquid 1ml, pour into then and melted the Nutrient agar culture 20ml that is cooled to 45 ℃, the rotation mixing, after solidifying, on agar plate, make a call to 3 apertures with the sterilization copper pipe of diameter 6mm, take out culture medium in the hole with aseptic nipper, in each hole, add 1.0g/ml, 0.5g/ml and 0.25g/ml medicinal liquid 0.1ml respectively, put 37 ℃ and cultivate 20h, take out plate, measure antibacterial circle diameter, repeat once, get the meansigma methods of secondary experiment.Experiment set routinely have only medicine not inoculated bacteria negative control and do not have the positive control of a medicine inoculated bacteria, the results are shown in Table 1.
Table 1 cough-relieving Mulberry Fructus Pruni granule is to the bacteriostasis of reference culture and clinical isolates strain
| Agent dose thing (g/ ml) | Antibacterial circle diameter (mm) | |||||||||||||||
| The standard escherichia coli | The standard bacillus pumilus | Escherichia coli | Staphylococcus aureus | The citric acid enterobacteria | Bacillus pyocyaneus | Kerekou pneumonia hundred Salmonellas | Standard hay bacterium | Standard Resina garciniae bacterium | Standard gold Portugal bacterium | Acinetobacter calcoaceticus | The table staphylococcus | The false monospore bacillus of Bulbus Allii Cepae | Staphylococcus hominis | Streptococcus | Bacillus proteus | |
| Cough-relieving mulberry apricot 1.0 heavy doses are organized dosage group cough-relieving mulberry apricot 0.2 the two coptis 0.1 powder-injection of 5 small dose group in the cough-relieving mulberry apricot particle 0.5 | 0.0 0.0 0.0 13. 0 | 0.0 0.0 0.0 10. 0 | 0.0 0.0 0.0 10.0 | 0.0 0.0 0.0 22. 0 | 0.0 0.0 0.0 16.0 | 0.0 0.0 0.0 19. 0 | 0.0 0.0 0.0 0.0 | 12. 0 10. 0 0.0 15. 0 | 12. 0 10. 0 0.0 21. 0 | 12. 0 0.0 0.0 22. 0 | 13. 0 10. 0 0.0 17. 5 | 14. 0 10. 0 0.0 21. 0 | 13. 0 10. 0 0.0 20. 0 | 15. 0 10. 0 0.0 20. 0 | 12.0 10.0 0.0 16.0 | 14.0 10.0 0.0 22.0 |
3.1.2 test tube method
Get each nutrition bacterial strain nutrient broth culture that 16h cultivates, do 10 with nutrient broth
-3Dilution is used for experiment, getting cough-relieving Mulberry Fructus Pruni granule medicinal liquid (200mg/ml) 0.4ml adds in the 1st pipe, get 1ml to the 2 pipes behind the mixing, drawing 1ml again from the 2nd pipe adds in the 3rd pipe, drawing 1ml from the 3rd pipe discards, the 4th pipe does not add medicinal liquid in contrast, and every pipe adds bacterium liquid 0.1ml, cultivates 18h for 37 ℃.Take out and observe, the results are shown in Table 2.
Table 2 cough-relieving Mulberry Fructus Pruni granule is to the MIC (test tube method) of reference culture and clinical isolates strain
| The bacterial strain name | Minimum inhibitory concentration (mg/ml) * |
| Standard gold staphylococcus aureus standard bacillus subtilis standard bacillus pumilus standard micrococcus luteus standard Escherichia coli Pseudomonas aeruginosa proteus acinetobacter calcoaceticus Escherichia coli citric acid enterobacteria streptococcus is had a liking for Fructus Hordei Germinatus pseudomonas staphylococcus aureus people staphylococcus table staphylococcus onion Pseudomonas | 50 50 50 50 100 100 200 50 200 200 100 200 50 100 100 50 |
*Twice empirical average value.
Experimental result shows: cough-relieving Mulberry Fructus Pruni granule has stronger bacteriostasis to standard gold Staphylococcus aureus, acinetobacter calcoaceticus, standard bacillus subtilis, standard micrococcus luteus, standard Bacillus pumilus, staphylococcus aureus, the false monospore bacillus of Bulbus Allii Cepae.
3.2 bacteriostatic experiment in the body
3.2.1 bacteriostasis to kerekou pneumonia Bai Shi coccus
Get 100 of Kunming mouses, male and female half and half are divided into 5 groups at random, are respectively (1) cough-relieving Mulberry Fructus Pruni granule small dose group, the heavily administration of 9.0g/kg Mus; (2) dosage group in the cough-relieving Mulberry Fructus Pruni granule, the heavily administration of 18.0g/kg Mus; (3) the heavy dose of group of cough-relieving Mulberry Fructus Pruni granule, the heavily administration of 36.0g/kg Mus; (4) positive controls, the heavily administration of SHUANGHUANGLIAN KOUFUYE 0.2ml/10g Mus; (5) blank group gives the 0.2ml/10g Mus heavy equivalent normal saline.It is 20ml/kg that each group is irritated the stomach volume, and continuous 8 days, the kerekou pneumonia hundred Salmonella liquid 0.5ml/ that 1h lumbar injection meat soup is cultivated after administration in the 5th day only observed the death toll of infecting mouse in the 72h, calculate mortality rate and protective rate.The results are shown in Table 3.
Table 3 cough-relieving Mulberry Fructus Pruni granule is antibacterial to kerekou pneumonia hundred Salmonellas in the mice body
| Group | Dosage | Number of animals (only) | Death toll (only) | Mortality rate (%) | Protective rate (%) |
| The heavy dose of group of dosage group cough-relieving Mulberry Fructus Pruni granule SHUANGHUANGLIAN KOUFUYE group in the blank group cough-relieving Mulberry Fructus Pruni granule small dose group cough-relieving Mulberry Fructus Pruni granule | 0.2ml/10g 9.0g/kg 18.0g/kg 36.0g/kg 0.2ml/10g | 20 20 20 20 20 | 19 19 18 17 17 | 95 95 90 85 85 | 0 0 5.0 11.1 11.1 |
The result shows: cough-relieving Mulberry Fructus Pruni granule does not have tangible bacteriostasis to mouse infection kerekou pneumonia hundred Salmonellas.
3.2.2 to aureus with inhibition
Get 100 of Kunming mouses, male and female half and half are divided into 5 groups at random, are respectively (1) cough-relieving Mulberry Fructus Pruni granule small dose group, the heavily administration of 9.0g/kg Mus; (2) dosage group in the cough-relieving Mulberry Fructus Pruni granule, the heavily administration of 18.0g/kg Mus; (3) the heavy dose of group of cough-relieving Mulberry Fructus Pruni granule, the heavily administration of 36.0g/kg Mus; (4) positive controls, the heavily administration of SHUANGHUANGLIAN KOUFUYE 0.2ml/10g Mus; (5) the blank group gives normal saline.It is 20ml.kg that each group is irritated the stomach volume
-1, continuous 8 days, the staphylococcus aureus bacterium liquid 0.5ml/ that 1h lumbar injection meat soup is cultivated after administration in the 5th day only observed the death toll in the 72h, calculates mortality rate and protective rate.The results are shown in Table 4.
Table 4 cough-relieving Mulberry Fructus Pruni granule is to infecting the protective effect of staphylococcus aureus in the mice body
| Group | Dosage | Number of animals (only) | Death toll (only) | Mortality rate (%) | Protective rate (%) |
| The heavy dose of group of dosage group cough-relieving Mulberry Fructus Pruni granule SHUANGHUANGLIAN KOUFUYE group in the blank group cough-relieving Mulberry Fructus Pruni granule small dose group cough-relieving Mulberry Fructus Pruni granule | 0.2ml/10g 9.0g/kg 18.0g/kg 36.0g/kg 0.2ml/10g | 20 20 20 20 20 | 16 10 8 4 4 | 80 50 40 20 25 | 0 37.5 50.0 * 75.0 ** 68.8 * |
Compare with the blank group:
*P＜0.05,
*P＜0.01
The result shows: cough-relieving Mulberry Fructus Pruni granule has significant protective effect to the mouse infection staphylococcus aureus when 9.0g/kg, 18.0g/kg, 36.0g/kg dosage.
3.3 antiviral experiment
3.3.1 extracorporeal antivirus effect experiment
3.3.1.1 cell culture median infective dose TCID50 titration
The virus chick embryo allantoic liquid is done 10 times of successive dilutions with culture medium.The culture fluid that grows up to 96 hole cellular plastic culture plates of cell monolayer is discarded, and each viral dilution degree is inoculated 4 holes, and every hole 100 μ l shake up, and 37 ℃ of absorption 1h abandon viral liquid, and Hank ' s liquid is washed 3 times, adds and keeps liquid, and every hole 0.1ml is put 37 ℃ of 5%CO
2Incubator is cultivated.Use the inverted microscope inspection every day, observe when no longer new pathological changes occurring with high dilution.Cytopathy below 25% is being+, 25～50% are ++, 50～75% are +++,＞75% is ++ ++.With pathological changes ++ be terminal point, calculate TCID50 with Reed and Muench method.TCID50 is 5.5 as a result.
3.3.1.2 medicine pair cell toxicity is identified
After cell grows up to cell monolayer, abandon culture medium, by 2 times of dilutions, every hole adds each dilution factor medicinal liquid 100 μ l with medicinal liquid, and each dilution factor adds 4 holes, 37 ℃ of 5%CO
2Incubator is cultivated.
With inverted microscope observation of cell pathological changes.Pair cell avirulence concentration is 10.0mg/ml.Application 10.0mg/ml, 5.0mg/ml concentration experimentize.
3.3.1.3 the outer antivirus action of cough-relieving Mulberry Fructus Pruni granule
Select well-grown Hep-2 cell, through digestion, eluting, cell counting is 2.8 * 10
5/ ml gets 0.1ml and is inoculated into 96 hole cellular plastic culture plates, 37 ℃ of 5%CO
2Cultivate 2d, make to grow up to cell monolayer.Abandon growth-promoting media, 30TCID
50Viral suspension host cells infected (0.1ml), 37 ℃ of absorption 1h abandon viral liquid, add the 0.1ml that keeps that contains medicinal liquid, each concentration 4 hole, 37 ℃ of 5%CO
2Cultivate, get normal cell contrast, virus control, virazole contrast simultaneously.Result of the test sees Table 5.
Table 5 cough-relieving Mulberry Fructus Pruni granule is to the influence of In vitro culture influenza virus
| Group | Dosage (mg/ml) | Cytopathy | |||
| 1 | 2 | 3 | 4 | ||
| Normal control papova matched group virazole contrast cough-relieving Mulberry Fructus Pruni granule cough-relieving Mulberry Fructus Pruni granule | - - 5 5 10 | - ++++ + ++++ +++ | - ++++ ++ ++++ +++ | - ++++ + +++ ++++ | - +++ + +++ +++ |
Annotate: n=4.
The result shows: cough-relieving Mulberry Fructus Pruni granule does not show the effect that directly suppresses influenza A virus in the extracorporeal antivirus effect experiment.
3.3.2 interior resisting virus experiment
3.3.2.1 virus causes the mensuration (LD of mice half mortality
50)
35 of Kunming mouses are divided into 7 groups, get influenza A virus (H
1N
1) 10 times of dilutions of chick embryo allantoic liquid (hemagglutinative titer is 640) do, 5 of each viral dilution concentration infecting mouses, 30 μ l/ Mus collunariums are observed death toll in 14 days, press Reed and Muench method and calculate LD
50Result: LD
50Be 6.5.
3.3.2.2 protective effect to the influenza a virus infection mice
Get 120 of Kunming mouses, body weight 12～14g.Be divided into 6 groups at random, 20 every group, ♀ ♂ half and half.(1) normal matched group: give the equivalent normal saline; (2) virus control group: give the equivalent normal saline; (3) virazole matched group: heavily administration of 0.07g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule I group, the heavily administration of 9.0g/kg Mus; (5) cough-relieving Mulberry Fructus Pruni granule II group, the heavily administration of 18.0g/kg Mus; (6) cough-relieving Mulberry Fructus Pruni granule III group, the heavily administration of 36.0g/kg Mus.
Above-mentioned each treated animal ig administration, 1 time/d, continuous 5d.2d after the administration, each organizes mice under the ether light anaesthesia, infects every Mus 30 μ l (15 LD50 challenging doses) with viral allantois drop nose.Observe zoogenetic infection sequela symptom, record infects death toll in the 15d of back.The result is as shown in table 6.
Table 6 cough-relieving Mulberry Fructus Pruni granule is to the protective effect of influenza virus infecting mouse death
| Group | Dosage (g/kg) | Number of animals (n) | Death toll (n) | Protective rate (%) |
| Normal control papova matched group virazole group cough-relieving Mulberry Fructus Pruni I group cough-relieving Mulberry Fructus Pruni II group cough-relieving Mulberry Fructus Pruni III group | - - 0.07 9.0 18.0 36.0 | 20 20 20 20 20 20 | 0 19 3 18 17 17 | - - 84.3 5 10.5 10.5 |
Experimental result shows: three dosage groups of cough-relieving Mulberry Fructus Pruni granule, death does not show significant protective effect to the influenza virus infecting mouse.
3.3.2.3 effect to mice influenza A virus pneumonia
Get 60 body weight 12～14g of Kunming mouse, be divided into 6 groups at random, 10 every group, male and female half and half: (1) blank group gives normal saline; (2) virus control group, the equivalent normal saline; (3) virazole group, the heavily administration of 0.07g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule I group, the heavily administration of 9.0g/kg Mus; (5) cough-relieving Mulberry Fructus Pruni granule II group, the heavily administration of 18.0g/kg Mus; (6) cough-relieving Mulberry Fructus Pruni granule III group, the heavily administration of 36.0g/kg Mus.Each organizes equal ig administration, and capacity is heavy for the 0.2ml/10g Mus, and 1 time/d, continuous 5d.Except that (1) group, each is organized mice and infected every Mus 30 μ l, 15 times of LD with viral allantois drop nose in second day after administration
50Challenging dose, normal control group infect the back and continue administration 4d with the normal saline collunarium.Respectively organize mice fasting 12h before the experiment, can't help water, weigh, take off cervical vertebra and put to death, dissect, the perusal pulmonary lesion is got full lung and is weighed, and calculates lung exponential quantity, lung index suppression ratio.Experimental result sees Table 7.
Table 7 cough-relieving Mulberry Fructus Pruni granule is to the effect of influenza virus infecting mouse pneumonia
| Group | Dosage (g/kg) | Animal (only) | The lung exponential quantity (X ± S) | Suppression ratio (%) |
| Blank papova matched group virazole group cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | - - 0.07 9.0 18.0 36.0 | 10 10 10 10 10 10 | 7.70±0.62 14.02±2.33 8.55±1.12 ** 11.26±4.56 10.83±1.88 * 9.00±1.08 ** | - - 39.02 19.69 22.75 35.81 |
Compare with the virus control group:
*P＜0.05,
*P＜0.01.
Shown in the result: the lung index of cough-relieving Mulberry Fructus Pruni granule 18.0g/kg and 36.0g/kg dosage group is starkly lower than the virus control group, shows that this medicine can alleviate the lesion degree of the mice pneumonia that influenza A virus causes.
3.4 cough-relieving, eliminate the phlegm and antiinflammatory experiment
3.4.1 antitussive action
3.4.1.1 mice ammonia draws the method for coughing
Get 60 of Kunming mouses, male, body weight 18～22g divides 6 groups: (1) blank group: give normal saline at random; (2) cough-relieving Mulberry Fructus Pruni granule I group: heavily administration of 9.0g/kg Mus; (3) cough-relieving Mulberry Fructus Pruni granule II group: heavily administration of 18.0g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule III group: heavily administration of 36.0g/kg Mus; (5) JIZHI TANGJIANG group: heavily administration of 22ml/kg Mus; (6) carbetapentane citrate group: heavily administration of 20mg/kg Mus.(1)～(4) the administration volume is 10ml/kg, and each is organized and is administered once every day, successive administration 5d, carbetapentane citrate group successive administration 3d.Last administration 45min places the bell jar of 500ml with mice, with ultrasound atomizer 25% strong aqua ammonia is sprayed for 5 seconds, observes and write down the number of times of cough in incubation period and 5 minutes of mouse cough then.The results are shown in Table 8.
Table 8 cough-relieving Mulberry Fructus Pruni granule is to drawing the influence of coughing incubation period and cough number of times (X ± S) due to the mice ammonia
| Group | Number of animals (only) | Dosage (g/kg) | Incubation period (s) | The cough number of times (inferior/5min) |
| Blank group JIZHI TANGJIANG group carbetapentane citrate group cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | 10 10 10 10 10 10 | - 22ml/kg 20mg/kg 9.0 18.0 36.0 | 20.60±7.75 48.80±29.38 ** 53.10±29.96 ** 23.30±12.10 30.60±17.53 47.00±30.15 * | 61.80±36.77 29.10±22.39 * 18.70±16.46 ** 61.00±35.56 48.80±29.55 30.30±23.97 * |
Compare with the blank group,
*P＜0.05,
*P＜0.01.
Experimental result shows: cough-relieving Mulberry Fructus Pruni granule 36.0g/kg dosage group can obviously prolong the ammonia induced mice draws and coughs incubation period, reduces the cough number of times of mice.
3.4.1.2 Cavia porcellus electrostimulation
Get 30 of Cavia porcelluss, the male and female dual-purpose, body weight 300～400g divides 6 groups: (1) blank group: give normal saline at random; (2) cough-relieving Mulberry Fructus Pruni granule I group: 3.7g/kg; (3) cough-relieving Mulberry Fructus Pruni granule II group: heavily administration of 7.5g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule III group: heavily administration of 15.0g/kg Mus; (5) carbetapentane citrate group: heavily administration of 7.0mg/kg Mus; (6) JIZHI TANGJIANG group: heavily administration of 8.6ml/kg Mus; (1)～(5) the administration volume is 10ml/kg, each is organized and is administered once every day, successive administration 5d, carbetapentane citrate group successive administration 3d, 30min after the last administration, urethane 1g/kg ip anesthesia with 25%, separate trachea, insert Y shape tracheal casing pipe, an arm links to each other with pressure transducer, connect two road physiology graphers, the recording respiration motion.Monopolar electrode with a platinum system is fixed in the trachea back side, and another indifferent electrode inserts in the subcutaneous tissue of chest (operation process 10min finishes).When administration 45min, adopt stimulus intensity 3.5V, pulse width 50ms, frequency 10 times/second, stimulation time 20s reads the cough number of times from recorder chart.The results are shown in Table 9.
Table 9 cough-relieving Mulberry Fructus Pruni granule is to the influence of the cough number of times due to the Cavia porcellus electricity irritation (X ± S)
| Group | Number of animals (only) | Dosage (g/kg) | The cough number of times (inferior/5min) |
| Blank group JIZHI TANGJIANG group carbetapentane citrate group cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | 5 5 5 5 5 5 | - 8.6ml/kg 7mg/kg 3.7 7.5 15.0 | 13.20±3.70 5.00±3.54 ** 1.80±1.48 ** 6.80±5.31 6.00±4.18 5.20±3.90 * |
Compare with the blank group,
*P＜0.05,
*P＜0.01.
Experimental result shows: cough-relieving Mulberry Fructus Pruni granule 15.0g/kg dosage group can obviously reduce the cough caused number of times of Cavia porcellus electricity irritation.In, small dose group and matched group relatively do not have significant difference, but still have the trend of effect.
3.4.2 expectorant test
3.4.2.1 the phenol red method of mice
Get 50 of Kunming mouses, male, body weight 20～25g divides 5 groups: (1) blank group: give the volume normal saline at random; (2) cough-relieving Mulberry Fructus Pruni granule I group: heavily administration of 9.0g/kg Mus; (3) cough-relieving Mulberry Fructus Pruni granule II group: heavily administration of 18.0g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule III group: heavily administration of 36.0g/kg Mus; (5) ammonia chloride group: heavily administration of 1.0g/kg Mus; Each is organized and is administered once every day, successive administration 3d, and the administration volume is 10ml/kg.Behind the last administration 30min, lumbar injection 5% phenol red normal saline solution 500mg/kg injected back 30 minutes, put to death animal, separated trachea, got 2.24mmol/LNaHCO with the 1ml syringe
3Solution 0.5ml, flushing air flue 3 times is drawn irrigating solution 0.5ml, repeats aforesaid operations 3 times, draws irrigating solution 1.5ml altogether, and flushing liquor is sucked test tube.At wavelength 546nm place, measure the OD value.The results are shown in Table 10.
Table 10 cough-relieving Mulberry Fructus Pruni granule is to the influence of phenol red output in the airway of mice (X ± S)
| Group | Number of animals (only) | Dosage (g/kg) | The OD value |
| Blank group ammonia chloride cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | 10 10 10 10 10 | - 1.0g/kg 9.0 18.0 36.0 | 0.205±0.05 0.662±0.182 ** 0.230±0.089 0.262±0.116 0.475±0.210 * |
Compare with the blank group,
*P＜0.05,
*P＜0.01.
Experimental result shows: cough-relieving Mulberry Fructus Pruni granule 36.0g/kg dosage group can obviously increase airway of mice phenol red output, relatively has notable difference with matched group.Show that cough-relieving Mulberry Fructus Pruni granule has the increase airway secretions, promote the effect that sputum is discharged.
3.4.2.2 rat capillary glass-tube method
Get 80 of rats, divide 5 groups at random: (1) blank group: give the volume normal saline; (2) cough-relieving Mulberry Fructus Pruni granule I group: heavily administration of 4.5g/kg Mus; (3) cough-relieving Mulberry Fructus Pruni granule II group: heavily administration of 9.0g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule III group: heavily administration of 18.0g/kg Mus; (5) ammonia chloride group: heavily administration of 0.5g/kg Mus.Fasting be can't help water 12 hours before the experiment.After the rat urethane 1g/kg intraperitoneal anesthesia, face upward the position and fix.Cut off neck middle part skin, isolate trachea, hit exactly between two cartilaginous rings at thyroid cartilage lower edge and prick an aperture, insert one of capillary glass tube then, make capillary tube just contact the trachea lower surface, so as to drawing the sputum at trachea rear portion with sharp-pointed injection needle.When being full of by liquid in the capillary tube, change one immediately.Draw the reduce phlegm effect of sputum length with capillary tube as medicine.After writing down preceding 2 hours normal branch and must measuring, gastric infusion continues to observe 4 hours secretory volumes again.The results are shown in Table 11.
Table 11 cough-relieving Mulberry Fructus Pruni granule is to the phlegm-dispelling functions of rat (X ± S)
| Group | Number of animals (only) | Dosage (g/kg) | Expectoration amount (cm) | |
| Before the administration | After the administration | |||
| Normal saline ammonia chloride cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | 16 16 16 16 16 | - 0.5 4.5 9.0 18.0 | 2.35±0.16 2.40±0.10 2.39±0.14 2.40±0.10 2.37±0.12 | 2.74±1.08 3.51±0.98 * 3.87±0.70 * 4.55±0.25 ** 3.96±0.60 * |
Compare with the blank group,
*P＜0.05,
*P＜0.01.
Experimental result shows, cough-relieving Mulberry Fructus Pruni granule 4.5g/kg, 9.0g/kg, 18.0g/kg administration can obviously increase the expectoration amount of rat.Show that cough-relieving Mulberry Fructus Pruni granule has significant resolve phlegm effect.
3.4.3 antiinflammatory action
3.4.3.1 cough-relieving Mulberry Fructus Pruni granule xylol causes the influence of mice auricle swelling
Get 60 of kunming mices, the male and female dual-purpose, 18～22g divides 7 groups: (1) blank group: give normal saline at random; (2) cough-relieving Mulberry Fructus Pruni granule I group: 9.0g/kg; (3) cough-relieving Mulberry Fructus Pruni granule II group: 18.0g/kg; (4) cough-relieving Mulberry Fructus Pruni granule III group: 36.0g/kg; (5) aspirin group: 0.3g/kg; (6) model group: give normal saline.Successive administration 5d, aspirin group successive administration 3d, the administration volume is 10ml/kg.Behind the last administration 1h, 30 μ l dimethylbenzene are applied to the wide two sides of mouse right ear cause inflammation, left side ear is not coated with in contrast, cause scorching back 45min and put to death mice, lay left and right auricle with the card punch of diameter 8mm, weigh, with left and right ear weight difference as the swelling degree, calculate swelling and suppress percentage rate, the results are shown in Table 12.
Table 12 cough-relieving Mulberry Fructus Pruni granule is to the influence of mouse ear caused by dimethylbenzene xylene inflammation (X ± S)
| Group | Number of animals (only) | Dosage (g/kg) | Left side ear heavy (mg) | Auris dextra heavy (mg) | Two ear swellings poor (mg) |
| Blank group model group aspirin group cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | 10 10 10 10 10 10 | - - 0.3 9.0 18.0 36.0 | 12.76±1.30 13.12±1.84 13.37±1.54 12.74±1.45 13.57±1.56 12.99±2.92 | 12.74±1.00 25.25±5.32## 15.84±1.44 23.71±4.12 21.89±3.45 18.99±4.10 ** | -0.02±0.57 12.13±5.78## 2.47±0.83 ** 10.97±3.94 8.32±3.48 6.00±3.86 * |
Compare with the blank group
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Experimental result shows: cough-relieving Mulberry Fructus Pruni granule 36.0g/kg can obviously alleviate dimethylbenzene induced mice ear swelling, wherein, the small dose group tool trend that has certain effect; Prompting cough-relieving Mulberry Fructus Pruni granule has certain antiinflammatory action.
3.4.3.2 cough-relieving Mulberry Fructus Pruni granule influences the mouse peritoneal capillary permeability
Get 50 of kunming mices, the male and female dual-purpose, body weight 18～22g divides 5 groups: (1) blank group: give isometric normal saline at random; (2) aspirin group: heavily administration of 0.3g/kg Mus; (3) cough-relieving Mulberry Fructus Pruni granule I group: heavily administration of 9.0g/kg Mus; (4) cough-relieving Mulberry Fructus Pruni granule II group: heavily administration of 18.0g/kg Mus; (5) cough-relieving Mulberry Fructus Pruni granule III group: heavily administration of 36.0g/kg Mus.Successive administration 5d, aspirin group successive administration 3d, the administration volume is 10ml/kg.After the last administration 45 minutes, it is heavy that every caudal vein is injected the blue 0.1ml/10g Mus of 0.5% ivens, lumbar injection 0.6%HAc 0.2ml/ only immediately, taking off cervical vertebra after 20 minutes puts to death, divide several to wash the abdominal cavity with the 6ml normal saline, behind the sucking-off cleaning mixture, add normal saline to 10ml, centrifugal 15 minutes of 3000rpm; Get supernatant in 590nm place colorimetric, record OD value the results are shown in Table 13.
Table 13 cough-relieving Mulberry Fructus Pruni granule is to mouse peritoneal capillary permeability influence (X ± S)
| Group | Number of animals (only) | Dosage (g/kg) | The OD value |
| Blank group aspirin group cough-relieving Mulberry Fructus Pruni granule I group cough-relieving Mulberry Fructus Pruni granule II group cough-relieving Mulberry Fructus Pruni granule III group | 10 10 10 10 10 | - 0.3 9.0 18.0 36.0 | 0.437±0.108 0.198±0.064 ** 0.334±0.151 0.229±0.113 ** 0.216±0.069 ** |
Compare with matched group,
*P＜0.05,
*P＜0.01.
Experimental result shows: the mouse peritoneal capillary permeability that cough-relieving Mulberry Fructus Pruni granule 18.0g/kg and 36.0g/kg dosage group can significantly suppress due to the HAc increases.
Claims (4)
1, a kind of extract and extracting method for the treatment of the combined traditional Chinese medicine material of respiratory system disease is characterized in that the formulation by weight of combined traditional Chinese medicine material extract raw material is:
Folium Mori 400～600 Radix Peucedanis 400～600 Radix Scutellariaes 400～600
Semen Armeniacae Amarum 400～600 Radix Platycodoniss 160～240 Bulbus Fritillariae Thunbergiis 400～600
Folium Eriobotryae 400～600 Radix Adenophoraes 400～600 Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens)s 400～600
Pericarpium Citri Reticulatae 240～360 Radix Glycyrrhizaes 120～180
(a) Folium Mori, Pericarpium Citri Reticulatae added 4～8 times of water gagings immersions after 2～4 hours, and steam distillation extracts volatile oil, collects the distillate of 4～10 times of amounts, and distillate gets Folium Mori and Pericarpium Citri Reticulatae volatile oil after redistillation-cold preservation;
(b) get after medicinal residues after the distillation of above-mentioned Folium Mori, Pericarpium Citri Reticulatae and Radix Peucedani, Folium Eriobotryae, Radix Adenophorae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae soak 0.5～2.0 hour, decoct 2～4 times, each 2～3 hours, each 4～8 times of amounts of water, collecting decoction, filter, filtrate is concentrated into 50 ℃ of following relative densities 1.05～1.1, gets water extract; Get Radix Scutellariae, Semen Armeniacae Amarum, Bulbus Fritillariae Thunbergii, Radix Platycodonis, add 50～80% soak with ethanol earlier after 0.5～2.0 hour, heating and refluxing extraction 2～4 times, each 1.0～2.0 hours, each ethanol consumption was 4～7 times of amounts, merge extractive liquid,, filter, decompression filtrate recycling ethanol, and be concentrated into 50 ℃ of following relative densities 1.05～1.1, get alcohol extract; Merge above water extract, alcohol extract, mixing gets combined traditional Chinese medicine material liquid extract;
Said method is the extracting method of extract of the combined traditional Chinese medicine material of described treatment respiratory system disease; Folium Mori and Pericarpium Citri Reticulatae volatile oil and combined traditional Chinese medicine material liquid extract are the extract of the combined traditional Chinese medicine material of described treatment respiratory system disease.
2, the extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease according to claim 1, it is characterized in that by beta-schardinger dextrin-: Folium Mori and Pericarpium Citri Reticulatae volatile oil are 6～9: 1 weight ratio, under 20～40 ℃ enclose temperature, Folium Mori and Pericarpium Citri Reticulatae volatile oil beta-cyclodextrin inclusion compound that (a) step is obtained, the enclose time is 2.5～3.5 hours, gets the Benexate Hydrochloride of Folium Mori and Pericarpium Citri Reticulatae volatile oil; The combined traditional Chinese medicine material liquid extract that (b) step is obtained concentrates again, and drying is pulverized the Benexate Hydrochloride that adds Folium Mori and Pericarpium Citri Reticulatae volatile oil, and mixing is granulated, and makes the described granule of pharmaceutics, capsule and tablet.
3, the extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease according to claim 1, it is characterized in that the combined traditional Chinese medicine material liquid extract that (b) step is obtained adds dispersant, add Folium Mori and the Pericarpium Citri Reticulatae volatile oil that (a) step obtains again, mixing is made soft capsule.
4, the extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease according to claim 1, it is characterized in that the combined traditional Chinese medicine material liquid extract that (b) step is obtained adds Folium Mori and the Pericarpium Citri Reticulatae volatile oil that (a) step obtains, and makes oral liquid by the described conventional method of pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100417340A CN100542578C (en) | 2004-08-15 | 2004-08-15 | The extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100417340A CN100542578C (en) | 2004-08-15 | 2004-08-15 | The extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733194A true CN1733194A (en) | 2006-02-15 |
| CN100542578C CN100542578C (en) | 2009-09-23 |
Family
ID=36075949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100417340A Expired - Lifetime CN100542578C (en) | 2004-08-15 | 2004-08-15 | The extract and the extracting method of the combined traditional Chinese medicine material of treatment respiratory system disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100542578C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939445B (en) * | 2006-09-21 | 2012-03-14 | 福州大学 | Preparation and use for loquat-leaf extract |
| CN103330817A (en) * | 2013-05-28 | 2013-10-02 | 陈松 | Traditional Chinese medicine for treating bronchitis |
| CN103623203A (en) * | 2013-12-09 | 2014-03-12 | 百花医药集团股份有限公司 | Method for preparing cough-suppressing oral preparation |
| CN103989911A (en) * | 2014-06-12 | 2014-08-20 | 路明芳 | Traditional Chinese medicine for treating pertussis |
| CN104225328A (en) * | 2014-09-29 | 2014-12-24 | 洛阳御平国生物科技有限公司 | Traditional Chinese medicine formula for treating bronchiectasis |
| CN105796853A (en) * | 2016-04-07 | 2016-07-27 | 刘爱红 | Oral Chinese herbal preparation for treating coughs |
| CN113274330A (en) * | 2021-06-09 | 2021-08-20 | 浙江曲蔓地生物科技有限公司 | Mulberry leaf volatile oil-water mixture and application thereof in skin care products |
-
2004
- 2004-08-15 CN CNB2004100417340A patent/CN100542578C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939445B (en) * | 2006-09-21 | 2012-03-14 | 福州大学 | Preparation and use for loquat-leaf extract |
| CN103330817A (en) * | 2013-05-28 | 2013-10-02 | 陈松 | Traditional Chinese medicine for treating bronchitis |
| CN103623203A (en) * | 2013-12-09 | 2014-03-12 | 百花医药集团股份有限公司 | Method for preparing cough-suppressing oral preparation |
| CN103623203B (en) * | 2013-12-09 | 2015-08-26 | 百花医药集团股份有限公司 | A kind of preparation method of dimethoxanate oral formulations |
| CN103989911A (en) * | 2014-06-12 | 2014-08-20 | 路明芳 | Traditional Chinese medicine for treating pertussis |
| CN104225328A (en) * | 2014-09-29 | 2014-12-24 | 洛阳御平国生物科技有限公司 | Traditional Chinese medicine formula for treating bronchiectasis |
| CN105796853A (en) * | 2016-04-07 | 2016-07-27 | 刘爱红 | Oral Chinese herbal preparation for treating coughs |
| CN113274330A (en) * | 2021-06-09 | 2021-08-20 | 浙江曲蔓地生物科技有限公司 | Mulberry leaf volatile oil-water mixture and application thereof in skin care products |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100542578C (en) | 2009-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN102526568B (en) | Traditional Chinese medicine compound composition | |
| CN1733194A (en) | Extract of combined Chinese traditional medicinal crops for curing diseases of respiratory system and extracting method | |
| CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN1957994A (en) | Animal use compound medicament with effect for clearing away the heat-evil and expelling superficial evils, and preparation method | |
| CN1958008A (en) | Animal use compound medicament with effects of removing toxic heat, and preparation method | |
| CN105726920A (en) | Anti-PM2.5 chewable tablets and preparing method thereof | |
| CN1323668C (en) | Pharmaceutical compositions and its application | |
| CN1698691A (en) | Medicine for treating cough due to lung heat/toxin and preparation method thereof | |
| CN101077380A (en) | Antivirus medicinal composition and preparation method thereof | |
| CN111084862B (en) | Traditional Chinese medicine oral liquid for preventing and treating lung heat cough and asthma of poultry and preparation method thereof | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1876151A (en) | A pharmaceutical composition for treating cold, its preparation method and use | |
| CN1813956A (en) | Medicine composition for preventing and controlling respiratory tract virus and bacterial infection of birds and preparing method | |
| CN1698752A (en) | Chinese medicinal tea bag for treating acute and chronic pharyngitis and its production method | |
| CN103705568A (en) | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry | |
| CN1593558A (en) | Sarcandra extract and its application | |
| CN116036188B (en) | Traditional Chinese medicine composition for preventing and treating chicken coccidiosis as well as preparation method and application thereof | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN1270734C (en) | Deal apple chrysanthemum preparation for treating throat disease | |
| CN1593564A (en) | Medicine for treating cold and its preparing process | |
| CN1264510C (en) | Application of geldanamycin (C-3559) preparation of medicine for curing genital tract infection of condyloma accuminatum and herpes virus and on preparation of medicine for curing poliomyelitis | |
| CN1957998A (en) | Animal use compound medicament with effects of removing toxic heat, removing heat from the blood to stop bleeding, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: KANGYUAN PHARMCEUTICAL CO., LTD. Free format text: FORMER OWNER: JIANGSU ZEUKOV PHARMACEUTICAL S. + T. INC. Effective date: 20121022 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222001 LIANYUNGANG, JIANGSU PROVINCE TO: 222047 LIANYUNGANG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121022 Address after: 222047 Jiangning economic and Technological Development Zone, Jiangsu, Lianyungang industrial city Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Address before: 222001 Jiangsu Province, Lianyungang city Sinpo District Haichang Road No. 58 Patentee before: Jiangsu Zeukov Pharmaceutical S. & T. Inc. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090923 |